DEXMEDETOMIDINE HYDROCHLORIDE
Manufacturer: CIVICA, INC.
Score: 141.0
Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a relatively selective alpha 2-adrenergic agonist indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting and for sedation of non-intubated patients prior to and/or during surgical and other procedures. The drug has a rapid distribution phase with a distribution half-life of approximately 6 minutes and a terminal elimination half-life of approximately 2 hours. Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered by intravenous infusion for up to 24 hours. The most common adverse reactions include hypotension, bradycardia, and dry mouth. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection should be administered using a controlled infusion device and the dosage should be individualized and titrated to desired clinical response.
Hypotension, bradycardia, and sinus arrest have been reported with the use of dexmedetomidine hydrochloride in 0.9% sodium chloride injection
Dosage reductions may need to be considered for adult patients with hepatic impairment and geriatric patients
Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour
Not established
Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour
Not established
DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Baxter Healthcare Corporation
DEXMEDETOMIDINE HCL
Medical Purchasing Solutions, LLC
REMIFENTANIL HYDROCHLORIDE
Mylan Institutional LLC